AHA comments on the Joint Commission’s recently proposed standards for perinatal safety.
Letters
Throughout the year, the AHA comments on a vast number of proposed and interim final rules put forth by the federal regulatory agencies. In addition, AHA communicates with federal legislators to convey the hospital field's position on potential legislative changes that would impact patients and patient care. Below are the most recent letters from the AHA to these bodies.
Latest
AHA letter to Representative Brad Schneider expressing support for legislation, H.R. 3414, the Opioid Workforce Act of 2019,
AHA urges the Antitrust Division of the Department of Justice (“DOJ”) to investigate thoroughly Centen
America’s hospitals and health systems are committed to the goal of affordable, comprehensive health insurance for every American. However, “Medicare for All” is not the solution. Instead, we should build upon and improve our existing system to increase access to coverage and comprehensive health benefits.
AHA letter to Senator Richard J. Durbin expressing support for legislation, S.
AHA comments on the Medicaid and CHIP Payment and Access Commission’s proposed recommendations related to the Medicaid Disproportionate Share Hospital (DSH) program.
AHA comments on the Medicaid and CHIP Payment and Access Commission’s proposed recommendations related to the Medicaid Disproportionate Share Hospital (DSH) program.
The Children’s Hospitals Graduate Medical Education (CHGME) program is a vital investment in strengthening the pediatric workforce and access to care for children.
Health care is changing rapidly. The rise of consumerism, the digital economy, precision medicine, predictive analytics, artificial intelligence, new high-tech entrants to the health care sector and affordability pressures all serve as catalysts for change. And America’s hospitals and health systems are leading the way forward. They continue to play an important role in serving our communities to meet today’s challenges and create a healthier tomorrow.
AHA letter to Ways and Means Committee on the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act (H.R. 2113.